Redhill Biopharma Ltd. Form 6-K Filing Summary

Redhill Biopharma Ltd. has completed several significant transactions in the third quarter of 2026. On August 27, 2026, the company sold its 70% interest in Talicia Holdings Inc. to a subsidiary of Apotex Health Corp. for an upfront payment of $18.0 million, with potential additional payments of up to $35.0 million based on sales milestones. A transition services agreement was also executed with Apotex. Furthermore, on August 28, 2026, Redhill Biopharma entered into a License and Commercial Supply Agreement with Ferring Pharmaceuticals, granting Ferring exclusive global commercialization rights to Rebyota® and exclusive U.S. rights to Clenpiq®. This agreement involved an upfront payment of $12 million, with provisions for tiered royalties, potential sales milestones, and other contingent payments, as well as the acquisition of existing Rebyota® inventory under deferred payment terms. As a result of these transactions and other third-quarter activities, the company's stockholders' equity is estimated to exceed $5 million as of September 30, 2026. This report is incorporated by reference into various registration statements filed with the SEC.